CAMP4 Therapeutics Corp
CAMP
NASDAQ
Biotechnology
$5.44
USD
+0.94 (+20.89%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $219.13M
Volume 408.3K
Revenue
$3.93M
TTM
-97.1%
YoY
Gross Margin
100%
TTM
+163.4%
YoY
Net Income
$-86.30M
TTM
-154.1%
YoY
Operating Cash Flow
$-26.25M
TTM
-22.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.9 | 1.5 | 0.8 | 0.3 | 1.3 |
YoY Growth | -98.8% | -97.6% | — | -46.6% | +50.8% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.9 | 1.5 | 0.8 | 0.3 | 1.3 |
Selling, General & Administrative | 3.8 | 4.2 | 4.6 | 4.8 | 4.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 |
Total Operating Expenses | 14.0 | 14.5 | 14.4 | 13.1 | 14.4 |
Operating Income | -13.1 | -13.0 | -13.7 | -12.8 | -13.1 |
EBITDA | -12.7 | -12.6 | -12.7 | -12.4 | -12.6 |
Other Income / Expense | 0.1 | -0.0 | -1.9 | -28.2 | -6.2 |
Total Other Income / Expense | 0.7 | 0.4 | -1.4 | -27.5 | -5.3 |
Income Before Income Taxes | -12.4 | -12.6 | -15.1 | -40.3 | -18.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -12.4 | -12.6 | -15.1 | -40.3 | -18.3 |
Consolidated Net Income / Loss | -12.4 | -12.6 | -15.1 | -40.3 | -18.3 |
Net Income Attributable to Common Shareholders | -12.4 | -12.6 | -15.1 | -40.3 | -18.3 |
Basic EPS | -$0.62 | -$0.62 | -$0.55 | -$0.75 | -$0.32 |
Diluted EPS | -$0.62 | -$0.62 | -$0.55 | -$0.75 | -$0.32 |
Basic Shares Outstanding | 20.2M | 20.2M | 27.3M | 53.9M | 57.9M |
Diluted Shares Outstanding | 20.2M | 20.2M | 27.3M | 53.9M | 57.9M |